A comparative study of single-dose treatment of chancroid using thiamphenicol versus Azithromycin
Braz. j. infect. dis
;
13(3): 218-220, June 2009. tab
Article
in English
| LILACS
| ID: lil-538523
ABSTRACT
A study was conducted in São Paulo, Brazil, to compare azithromycin with thiamphenicol for the single-dose treatment of chancroid. In all, 54 men with chancroid were tested. The etiology was determined by clinical characterization and direct bacterioscopy with Gram staining. None of the patients had positive serology or dark-field examination indicating active infection with Treponema pallidum. Genital infections due to Neisseria gonorrhoeae and herpes simplex virus were excluded by polymerase chain reaction testing. For 54 patients with chancroid, cure rates with single-dose treatment were 73 percent with azithromycin and 89 percent with thiamphenicol. HIV seropositivity was found to be associated with treatment failure (p=0.001). The treatment failed in all HIV positive patients treated with azithromycin (p=0.002) and this drug should be avoided in these co-infected patients. In the view of the authors, thiamphenicol is the most indicated single-dose regimen for chancroid treatment.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Thiamphenicol
/
Chancroid
/
AIDS-Related Opportunistic Infections
/
Azithromycin
/
Anti-Bacterial Agents
Type of study:
Etiology study
/
Incidence study
/
Observational study
/
Risk factors
Limits:
Humans
/
Male
Language:
English
Journal:
Braz. j. infect. dis
Journal subject:
Communicable Diseases
Year:
2009
Type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Santo Amaro University/BR
/
State University of Campinas/BR
/
São Paulo University/BR
Similar
MEDLINE
...
LILACS
LIS